Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Breast Cancer
Interventions: AZD9496 (Reference), AZD9496 Variant A, AZD9496 Variant B, AZD9496 Variant C, AZD9496 Variant D; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Smoking, Tobacco Use
Interventions: Product A, Product B, Product C, Product D, Product E, Product F, Product G; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pulmonary Arterial Hypertension
Interventions: Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks; Biological
Lead sponsor: Keros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more

Conditions: Healthy Volunteers, Schizophrenia
Interventions: TAK-041, TAK-041 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Wound Healing
Interventions: GSK1278863, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Infections, Bacterial
Interventions: Gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Dermatitis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more

Conditions: Healthy
Interventions: IMBRUVICA (Treatment A), Ibrutinib (Treatment B); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: 23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 20
States / cities: Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more

Conditions: Healthy
Interventions: MAP0004, IV Placebo (Saline), Placebo Inhaler, IV Dihydroergotamine Mesylate (DHE); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: CT-152 - Digital Therapeutic, Sham; Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 22 Years to 64 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Pancreatic Cancer
Interventions: Nab paclitaxel, Gemcitabine, Dociparstat; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 16
States / cities: Scottsdale, Arizona • Burbank, California • Greenbrae, California + 12 more

Conditions: Atopic Dermatitis
Interventions: Lutikizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: Fountain Hills, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Acute Pain
Interventions: K-285, Menthol; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Large B Cell Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, filgrastim, pegfilgrastim; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2021
U.S. locations: 47
States / cities: La Jolla, California • Mountain View, California • Palo Alto, California + 38 more

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Exocrine Pancreatic Insufficiency
Interventions: RELiZORB, Placebo; Device
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more

Conditions: Mild to Moderate Asthma
Interventions: fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate; Drug · Other
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more

Conditions: Dietary Supplement
Interventions: Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator; Dietary Supplement · Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tustin, California

Conditions: Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
Interventions: Norovirus -specific T-cell (NST) therapy; Biological
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Months to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Losmapimod, Placebo oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more

Conditions: Alzheimer's Disease
Interventions: LY2886721, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Healthy Volunteers
Interventions: Maribavir (400 mg), Maribavir (200 mg), Maribavir (800 mg); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Lyme Disease
Interventions: PCR based assay, Serology based assay, Tcell based assay; Diagnostic Test
Lead sponsor: Oxford Immunotec; Industry
Eligibility: 5 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 60
States / cities: Redding, California • New London, Connecticut • Norwalk, Connecticut + 53 more

Search by objective public record fields.

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects

CSD201002: Study to Assess Nicotine Uptake From P10 Nicotine Pouches

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of K-285 Compared With Menthol Gel for the Treatment of Delayed Onset Muscle Soreness (DOMS) in the Lower Extremity

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

A Safety Study of LY2886721 Single Doses in Healthy Subjects

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

Lyme Test Indication Combinations (LyTIC) Study